Amoy Diagnostics | GenomeWeb

Amoy Diagnostics

The test, which will be based on AmoyDx's proprietary real-time PCR technology, will identify cancer-associated mutations in the RAS gene family.

AmoyDx will develop and commercialize a series of oncology tests that use Illumina NGS technology, including the firm's TruSight Tumor 15 panel.

NEW YORK (GenomeWeb) — Chinese molecular diagnostics firm Amoy Diagnostics said today that four of its mutation analysis kits have received CE marking.

NEW YORK (GenomeWeb) – MoBiTec today announced a deal for the distribution of Amoy Diagnostics products in Germany.

NEW YORK (GenomeWeb) – Chinese molecular diagnostics firm Amoy Diagnostics this week announced it has received regulatory approval from the China Food and Drug Administration for two in vitro diagnostics kits.
The firm also said that the kits obtained CE marking in Europe.

NEW YORK (GenomeWeb News) – Amoy Diagnostics today said that it has reached an agreement with OxOnc Development to use Amoy's ROS1 Gene Fusions Detection Kits for a pivotal clinical trial of Pfizer's Xalkori (crizotinib).

NEW YORK (GenomeWeb News) –Amoy Diagnostics today said that China's State Food and Drug Administration has approved the company's EML4-ALK Fusion Gene Detection Kit for marketing in that country.

NEW YORK (GenomeWeb News) – Syapse, a Palo Alto, Calif.-based startup developing software for interpreting next-generation sequencing data to diagnose and treat patients, has raised $3 million in Series A venture capital funding.

NEW YORK (GenomeWeb News) – Trovagene said this week that it will collaborate with researchers at the University of Texas MD Anderson Cancer Center on detecting transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers.

Seegene this week introduced the Anyplex II STI-7 detection assay, a multiplex real-time PCR assay for several sexually transmitted infectious agents.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.